NZ589084A - Glucokinase activators - Google Patents
Glucokinase activatorsInfo
- Publication number
- NZ589084A NZ589084A NZ589084A NZ58908409A NZ589084A NZ 589084 A NZ589084 A NZ 589084A NZ 589084 A NZ589084 A NZ 589084A NZ 58908409 A NZ58908409 A NZ 58908409A NZ 589084 A NZ589084 A NZ 589084A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- hetero
- cycloalkyl
- bicycloaryl
- pyran
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title claims description 88
- 108010021582 Glucokinase Proteins 0.000 title claims description 88
- 239000012190 activator Substances 0.000 title description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 4
- LYMBHJTVTFRHIJ-INIZCTEOSA-N (2s)-2-(3-cyclopropylsulfonylpyrazol-1-yl)-n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@@H](C(=O)NC1=NC2=CC=C(N=C2S1)OC)N1N=C(C=C1)S(=O)(=O)C1CC1)C1CCOCC1 LYMBHJTVTFRHIJ-INIZCTEOSA-N 0.000 claims abstract 2
- LYMBHJTVTFRHIJ-UHFFFAOYSA-N 2-(3-cyclopropylsulfonylpyrazol-1-yl)-n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C2=NC(OC)=CC=C2N=C1NC(=O)C(N1N=C(C=C1)S(=O)(=O)C1CC1)CC1CCOCC1 LYMBHJTVTFRHIJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract 2
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2048
- 125000005842 heteroatom Chemical group 0.000 claims description 904
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 579
- 125000003118 aryl group Chemical group 0.000 claims description 381
- -1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 claims description 344
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 274
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 270
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 257
- 125000005843 halogen group Chemical group 0.000 claims description 249
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 234
- 125000001072 heteroaryl group Chemical group 0.000 claims description 223
- 229910052739 hydrogen Inorganic materials 0.000 claims description 179
- 239000001257 hydrogen Substances 0.000 claims description 179
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 167
- 125000004104 aryloxy group Chemical group 0.000 claims description 164
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 146
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 138
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 137
- 125000003545 alkoxy group Chemical group 0.000 claims description 132
- 125000003282 alkyl amino group Chemical group 0.000 claims description 129
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 107
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 96
- 125000004429 atom Chemical group 0.000 claims description 70
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 52
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims description 38
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 36
- 125000003368 amide group Chemical group 0.000 claims description 29
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 25
- 125000005518 carboxamido group Chemical group 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 20
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- UKFJOAZAZSQUJZ-QGZVFWFLSA-N (2R)-2-(4-cyclopropylsulfonyl-6-hydroxyindazol-1-yl)-N-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@@H](N1N=CC2=C(C=C(C=C21)O)S(=O)(=O)C1CC1)C(=O)NC=1SC(F)=CN=1)C1CCOCC1 UKFJOAZAZSQUJZ-QGZVFWFLSA-N 0.000 claims 1
- UKFJOAZAZSQUJZ-KRWDZBQOSA-N (2S)-2-(4-cyclopropylsulfonyl-6-hydroxyindazol-1-yl)-N-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@H](N1N=CC2=C(C=C(C=C21)O)S(=O)(=O)C1CC1)C(=O)NC=1SC(F)=CN=1)C1CCOCC1 UKFJOAZAZSQUJZ-KRWDZBQOSA-N 0.000 claims 1
- KCADKUALFIGJHV-MRXNPFEDSA-N (2r)-2-(4-cyclopentylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1N=CC(=C1)S(=O)(=O)C1CCCC1)CC1CCOCC1 KCADKUALFIGJHV-MRXNPFEDSA-N 0.000 claims 1
- WWSWNVIZJZADCC-LJQANCHMSA-N (2r)-2-(4-cyclopropylsulfonyl-5-fluoroindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@@H](CC2CCOCC2)N2C3=CC=C(F)C(=C3C=N2)S(=O)(=O)C2CC2)=N1 WWSWNVIZJZADCC-LJQANCHMSA-N 0.000 claims 1
- XYQFUCIVUHMUDH-LJQANCHMSA-N (2r)-2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound COC1=CC=C2N([C@H](CC3CCOCC3)C(=O)NC=3N=CC=NC=3)N=CC2=C1S(=O)(=O)C1CC1 XYQFUCIVUHMUDH-LJQANCHMSA-N 0.000 claims 1
- ABOUYICYKNTUHD-LJQANCHMSA-N (2r)-2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound COC1=CC=C2N([C@H](CC3CCOCC3)C(=O)NC3=NN(C)C=C3)N=CC2=C1S(=O)(=O)C1CC1 ABOUYICYKNTUHD-LJQANCHMSA-N 0.000 claims 1
- BVZJAMCFKWGLNJ-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound COC1=CC=C2N([C@H](CC3CCOCC3)C(=O)NC=3SC(F)=CN=3)N=CC2=C1S(=O)(=O)C1CC1 BVZJAMCFKWGLNJ-QGZVFWFLSA-N 0.000 claims 1
- GHELKQXDVLJGBS-LJQANCHMSA-N (2r)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@@H](CC1CCOCC1)N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 GHELKQXDVLJGBS-LJQANCHMSA-N 0.000 claims 1
- KSQIDLKRSFWITH-LJQANCHMSA-N (2r)-2-(4-cyclopropylsulfonylindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@@H](CC2CCOCC2)N2C3=CC=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 KSQIDLKRSFWITH-LJQANCHMSA-N 0.000 claims 1
- VFUKAAVEACENGY-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 VFUKAAVEACENGY-QGZVFWFLSA-N 0.000 claims 1
- CKDRXQFLSZIDBI-CQSZACIVSA-N (2r)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 CKDRXQFLSZIDBI-CQSZACIVSA-N 0.000 claims 1
- JYZIVUSLCKNWPM-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@H](C(=O)NC1=NC2=CC=C(N=C2S1)OC)N1N=CC(=C1)S(=O)(=O)C1CC1)C1CCOCC1 JYZIVUSLCKNWPM-QGZVFWFLSA-N 0.000 claims 1
- ICASRZHGWZSLKA-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@@H](CC1CCOCC1)N1C2=NC=CC(=C2C=N1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 ICASRZHGWZSLKA-QGZVFWFLSA-N 0.000 claims 1
- ARYWWKQGSXXOMW-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@@H](CC2CCOCC2)N2C3=NC=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 ARYWWKQGSXXOMW-QGZVFWFLSA-N 0.000 claims 1
- YKBDFPILEUOTGX-OAHLLOKOSA-N (2r)-2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1C2=NC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 YKBDFPILEUOTGX-OAHLLOKOSA-N 0.000 claims 1
- DISGNCPYSOHNKL-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@@H](CC1CCOCC1)N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 DISGNCPYSOHNKL-QGZVFWFLSA-N 0.000 claims 1
- KUFXUEYIWPFSHN-OAHLLOKOSA-N (2r)-2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KUFXUEYIWPFSHN-OAHLLOKOSA-N 0.000 claims 1
- IVRYXUUZXGHGFF-MRXNPFEDSA-N (2r)-2-(6-amino-4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C([C@@H](N1N=CC2=C(C=C(N=C21)N)S(=O)(=O)C1CC1)C(=O)NC=1N=CC=NC=1)C1CCOCC1 IVRYXUUZXGHGFF-MRXNPFEDSA-N 0.000 claims 1
- UCVQDAARHGLGBM-CQSZACIVSA-N (2r)-2-(6-amino-4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@@H](N1N=CC2=C(C=C(N=C21)N)S(=O)(=O)C1CC1)C(=O)NC=1SC(F)=CN=1)C1CCOCC1 UCVQDAARHGLGBM-CQSZACIVSA-N 0.000 claims 1
- YILOROXHYKMRCS-QGZVFWFLSA-N (2r)-2-(6-chloro-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1C2=CC(Cl)=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 YILOROXHYKMRCS-QGZVFWFLSA-N 0.000 claims 1
- XLQHBYCHEWPRHA-GOSISDBHSA-N (2r)-2-(6-cyano-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@H](N1C2=CC(=CC(=C2C=N1)S(=O)(=O)C1CC1)C#N)CC1CCOCC1 XLQHBYCHEWPRHA-GOSISDBHSA-N 0.000 claims 1
- BQSWORVDGGEXBI-MRXNPFEDSA-N (2r)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopentylsulfonylpyrazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@H](N1N=CC(=C1)S(=O)(=O)C1CCCC1)CC1CCOCC1 BQSWORVDGGEXBI-MRXNPFEDSA-N 0.000 claims 1
- AMNCFZVGAPBFJS-QGZVFWFLSA-N (2r)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@H](N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 AMNCFZVGAPBFJS-QGZVFWFLSA-N 0.000 claims 1
- CFAZNSRHYWJWBC-CQSZACIVSA-N (2r)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@H](N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 CFAZNSRHYWJWBC-CQSZACIVSA-N 0.000 claims 1
- ONNFBMFRNCTCOG-GOSISDBHSA-N (2r)-n-(5-chloro-1,3-thiazol-2-yl)-2-(5-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@H](N1C2=CC=C(C=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 ONNFBMFRNCTCOG-GOSISDBHSA-N 0.000 claims 1
- WWSWNVIZJZADCC-IBGZPJMESA-N (2s)-2-(4-cyclopropylsulfonyl-5-fluoroindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@H](CC2CCOCC2)N2C3=CC=C(F)C(=C3C=N2)S(=O)(=O)C2CC2)=N1 WWSWNVIZJZADCC-IBGZPJMESA-N 0.000 claims 1
- XYQFUCIVUHMUDH-IBGZPJMESA-N (2s)-2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound COC1=CC=C2N([C@@H](CC3CCOCC3)C(=O)NC=3N=CC=NC=3)N=CC2=C1S(=O)(=O)C1CC1 XYQFUCIVUHMUDH-IBGZPJMESA-N 0.000 claims 1
- ABOUYICYKNTUHD-IBGZPJMESA-N (2s)-2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound COC1=CC=C2N([C@@H](CC3CCOCC3)C(=O)NC3=NN(C)C=C3)N=CC2=C1S(=O)(=O)C1CC1 ABOUYICYKNTUHD-IBGZPJMESA-N 0.000 claims 1
- BTBPVWQJZDELHN-KRWDZBQOSA-N (2s)-2-(4-cyclopropylsulfonyl-6-fluoroindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](N1C2=CC(F)=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 BTBPVWQJZDELHN-KRWDZBQOSA-N 0.000 claims 1
- GHELKQXDVLJGBS-IBGZPJMESA-N (2s)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@H](CC1CCOCC1)N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 GHELKQXDVLJGBS-IBGZPJMESA-N 0.000 claims 1
- KSQIDLKRSFWITH-IBGZPJMESA-N (2s)-2-(4-cyclopropylsulfonylindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@H](CC2CCOCC2)N2C3=CC=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 KSQIDLKRSFWITH-IBGZPJMESA-N 0.000 claims 1
- CKDRXQFLSZIDBI-AWEZNQCLSA-N (2s)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 CKDRXQFLSZIDBI-AWEZNQCLSA-N 0.000 claims 1
- JYZIVUSLCKNWPM-KRWDZBQOSA-N (2s)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@@H](C(=O)NC1=NC2=CC=C(N=C2S1)OC)N1N=CC(=C1)S(=O)(=O)C1CC1)C1CCOCC1 JYZIVUSLCKNWPM-KRWDZBQOSA-N 0.000 claims 1
- ICASRZHGWZSLKA-KRWDZBQOSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@H](CC1CCOCC1)N1C2=NC=CC(=C2C=N1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 ICASRZHGWZSLKA-KRWDZBQOSA-N 0.000 claims 1
- ARYWWKQGSXXOMW-KRWDZBQOSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@H](CC2CCOCC2)N2C3=NC=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 ARYWWKQGSXXOMW-KRWDZBQOSA-N 0.000 claims 1
- YKBDFPILEUOTGX-HNNXBMFYSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](N1C2=NC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 YKBDFPILEUOTGX-HNNXBMFYSA-N 0.000 claims 1
- DISGNCPYSOHNKL-KRWDZBQOSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@H](CC1CCOCC1)N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 DISGNCPYSOHNKL-KRWDZBQOSA-N 0.000 claims 1
- RYFMDZKJPZKOAK-KRWDZBQOSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@H](CC2CCOCC2)N2C3=CN=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 RYFMDZKJPZKOAK-KRWDZBQOSA-N 0.000 claims 1
- KUFXUEYIWPFSHN-HNNXBMFYSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KUFXUEYIWPFSHN-HNNXBMFYSA-N 0.000 claims 1
- DSXYFRHBEHZZQH-AWEZNQCLSA-N (2s)-2-(4-tert-butylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=C(S(=O)(=O)C(C)(C)C)C=NN1[C@H](C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 DSXYFRHBEHZZQH-AWEZNQCLSA-N 0.000 claims 1
- IVRYXUUZXGHGFF-INIZCTEOSA-N (2s)-2-(6-amino-4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C([C@H](N1N=CC2=C(C=C(N=C21)N)S(=O)(=O)C1CC1)C(=O)NC=1N=CC=NC=1)C1CCOCC1 IVRYXUUZXGHGFF-INIZCTEOSA-N 0.000 claims 1
- UCVQDAARHGLGBM-AWEZNQCLSA-N (2s)-2-(6-amino-4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@H](N1N=CC2=C(C=C(N=C21)N)S(=O)(=O)C1CC1)C(=O)NC=1SC(F)=CN=1)C1CCOCC1 UCVQDAARHGLGBM-AWEZNQCLSA-N 0.000 claims 1
- XLQHBYCHEWPRHA-SFHVURJKSA-N (2s)-2-(6-cyano-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](N1C2=CC(=CC(=C2C=N1)S(=O)(=O)C1CC1)C#N)CC1CCOCC1 XLQHBYCHEWPRHA-SFHVURJKSA-N 0.000 claims 1
- AMNCFZVGAPBFJS-KRWDZBQOSA-N (2s)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@@H](N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 AMNCFZVGAPBFJS-KRWDZBQOSA-N 0.000 claims 1
- CFAZNSRHYWJWBC-AWEZNQCLSA-N (2s)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@@H](N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 CFAZNSRHYWJWBC-AWEZNQCLSA-N 0.000 claims 1
- ONNFBMFRNCTCOG-SFHVURJKSA-N (2s)-n-(5-chloro-1,3-thiazol-2-yl)-2-(5-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@@H](N1C2=CC=C(C=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 ONNFBMFRNCTCOG-SFHVURJKSA-N 0.000 claims 1
- KCADKUALFIGJHV-UHFFFAOYSA-N 2-(4-cyclopentylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C1CCCC1)CC1CCOCC1 KCADKUALFIGJHV-UHFFFAOYSA-N 0.000 claims 1
- UYYCRVULRCEENV-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-3,5-dimethylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound CC1=C(S(=O)(=O)C2CC2)C(C)=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 UYYCRVULRCEENV-UHFFFAOYSA-N 0.000 claims 1
- TUPGTQLXJWRMGX-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-fluoroindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound FC1=CC=C2N(C(CC3CCOCC3)C(=O)NC=3N=CC=NC=3)N=CC2=C1S(=O)(=O)C1CC1 TUPGTQLXJWRMGX-UHFFFAOYSA-N 0.000 claims 1
- BGIVDRATWYMFPE-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-fluoroindazol-1-yl)-n-(1-ethylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CCN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=CC=C(F)C(=C3C=N2)S(=O)(=O)C2CC2)=N1 BGIVDRATWYMFPE-UHFFFAOYSA-N 0.000 claims 1
- WWSWNVIZJZADCC-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-fluoroindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=CC=C(F)C(=C3C=N2)S(=O)(=O)C2CC2)=N1 WWSWNVIZJZADCC-UHFFFAOYSA-N 0.000 claims 1
- REFCAUYDZIRZFX-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-fluoroindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CC=C(F)C(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 REFCAUYDZIRZFX-UHFFFAOYSA-N 0.000 claims 1
- KFWJWVYKUAFUBU-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-hydroxyindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound OC1=CC=C2N(C(CC3CCOCC3)C(=O)NC=3SC(F)=CN=3)N=CC2=C1S(=O)(=O)C1CC1 KFWJWVYKUAFUBU-UHFFFAOYSA-N 0.000 claims 1
- XYQFUCIVUHMUDH-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound COC1=CC=C2N(C(CC3CCOCC3)C(=O)NC=3N=CC=NC=3)N=CC2=C1S(=O)(=O)C1CC1 XYQFUCIVUHMUDH-UHFFFAOYSA-N 0.000 claims 1
- ABOUYICYKNTUHD-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound COC1=CC=C2N(C(CC3CCOCC3)C(=O)NC3=NN(C)C=C3)N=CC2=C1S(=O)(=O)C1CC1 ABOUYICYKNTUHD-UHFFFAOYSA-N 0.000 claims 1
- BVZJAMCFKWGLNJ-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-methoxyindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound COC1=CC=C2N(C(CC3CCOCC3)C(=O)NC=3SC(F)=CN=3)N=CC2=C1S(=O)(=O)C1CC1 BVZJAMCFKWGLNJ-UHFFFAOYSA-N 0.000 claims 1
- VEKNFKDPXNRBMS-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-methylindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound CC1=CC=C2N(C(CC3CCOCC3)C(=O)NC=3N=CC=NC=3)N=CC2=C1S(=O)(=O)C1CC1 VEKNFKDPXNRBMS-UHFFFAOYSA-N 0.000 claims 1
- SCOXNBXHANFRTH-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-5-methylindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CC1=CC=C2N(C(CC3CCOCC3)C(=O)NC3=NN(C)C=C3)N=CC2=C1S(=O)(=O)C1CC1 SCOXNBXHANFRTH-UHFFFAOYSA-N 0.000 claims 1
- BSPWAZZHMBUSNA-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-fluoroindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C12=CC(F)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1N=CC=NC=1)CC1CCOCC1 BSPWAZZHMBUSNA-UHFFFAOYSA-N 0.000 claims 1
- XUEBBRQEFRPJPO-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-fluoroindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=CC(F)=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 XUEBBRQEFRPJPO-UHFFFAOYSA-N 0.000 claims 1
- BTBPVWQJZDELHN-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-fluoroindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CC(F)=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 BTBPVWQJZDELHN-UHFFFAOYSA-N 0.000 claims 1
- UKFJOAZAZSQUJZ-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-hydroxyindazol-1-yl)-N-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(O)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 UKFJOAZAZSQUJZ-UHFFFAOYSA-N 0.000 claims 1
- KIHRPYDSDMFBJT-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-methoxyindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(OC)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC1=NN(C)C=C1)CC1CCOCC1 KIHRPYDSDMFBJT-UHFFFAOYSA-N 0.000 claims 1
- DHHJSNCNVAZFJD-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-methoxyindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(OC)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 DHHJSNCNVAZFJD-UHFFFAOYSA-N 0.000 claims 1
- XALYPPVXWPKDPG-UHFFFAOYSA-N 2-(4-cyclopropylsulfonyl-6-methylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(C)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 XALYPPVXWPKDPG-UHFFFAOYSA-N 0.000 claims 1
- GHELKQXDVLJGBS-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1COCCC1CC(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=CN=CC=N1 GHELKQXDVLJGBS-UHFFFAOYSA-N 0.000 claims 1
- JELVQTZUMCGEDL-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)-n-pyrimidin-4-ylpropanamide Chemical compound C1COCCC1CC(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=CC=NC=N1 JELVQTZUMCGEDL-UHFFFAOYSA-N 0.000 claims 1
- ZYSPDRWRYRMUPF-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylindazol-1-yl)-n-(1,5-dimethylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C(C)=CC(NC(=O)C(CC2CCOCC2)N2C3=CC=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 ZYSPDRWRYRMUPF-UHFFFAOYSA-N 0.000 claims 1
- WGUMMPKGYSSUMR-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylindazol-1-yl)-n-(3,5-difluoropyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound FC1=CC(F)=CN=C1NC(=O)C(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 WGUMMPKGYSSUMR-UHFFFAOYSA-N 0.000 claims 1
- VFUKAAVEACENGY-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 VFUKAAVEACENGY-UHFFFAOYSA-N 0.000 claims 1
- KPRQPTJCLNSJOG-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylindazol-1-yl)-n-(6-methylpyridazin-3-yl)-3-(oxan-4-yl)propanamide Chemical compound N1=NC(C)=CC=C1NC(=O)C(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KPRQPTJCLNSJOG-UHFFFAOYSA-N 0.000 claims 1
- CKDRXQFLSZIDBI-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 CKDRXQFLSZIDBI-UHFFFAOYSA-N 0.000 claims 1
- JYZIVUSLCKNWPM-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazol-1-yl)-n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C2=NC(OC)=CC=C2N=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 JYZIVUSLCKNWPM-UHFFFAOYSA-N 0.000 claims 1
- ICASRZHGWZSLKA-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1COCCC1CC(N1C2=NC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=CN=CC=N1 ICASRZHGWZSLKA-UHFFFAOYSA-N 0.000 claims 1
- ARYWWKQGSXXOMW-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=NC=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 ARYWWKQGSXXOMW-UHFFFAOYSA-N 0.000 claims 1
- YKBDFPILEUOTGX-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=NC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 YKBDFPILEUOTGX-UHFFFAOYSA-N 0.000 claims 1
- DISGNCPYSOHNKL-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1COCCC1CC(N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=CN=CC=N1 DISGNCPYSOHNKL-UHFFFAOYSA-N 0.000 claims 1
- RYFMDZKJPZKOAK-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=CN=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 RYFMDZKJPZKOAK-UHFFFAOYSA-N 0.000 claims 1
- KUFXUEYIWPFSHN-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KUFXUEYIWPFSHN-UHFFFAOYSA-N 0.000 claims 1
- DSXYFRHBEHZZQH-UHFFFAOYSA-N 2-(4-tert-butylsulfonylpyrazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=C(S(=O)(=O)C(C)(C)C)C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 DSXYFRHBEHZZQH-UHFFFAOYSA-N 0.000 claims 1
- PAGQQIDOMGYXDP-UHFFFAOYSA-N 2-(5-bromo-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CC=C(Br)C(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 PAGQQIDOMGYXDP-UHFFFAOYSA-N 0.000 claims 1
- LHLXLDHLVGXFIB-UHFFFAOYSA-N 2-(6-amino-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(N)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 LHLXLDHLVGXFIB-UHFFFAOYSA-N 0.000 claims 1
- IVRYXUUZXGHGFF-UHFFFAOYSA-N 2-(6-amino-4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C12=NC(N)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1N=CC=NC=1)CC1CCOCC1 IVRYXUUZXGHGFF-UHFFFAOYSA-N 0.000 claims 1
- OBGVCTJLPZNXIW-UHFFFAOYSA-N 2-(6-amino-4-cyclopropylsulfonylpyrazolo[3,4-b]pyridin-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=NC(N)=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 OBGVCTJLPZNXIW-UHFFFAOYSA-N 0.000 claims 1
- UKOHLYFBEQVKRW-UHFFFAOYSA-N 2-(6-chloro-4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C12=CC(Cl)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1N=CC=NC=1)CC1CCOCC1 UKOHLYFBEQVKRW-UHFFFAOYSA-N 0.000 claims 1
- SQLBLEQZFKLJDH-UHFFFAOYSA-N 2-(6-chloro-4-cyclopropylsulfonylindazol-1-yl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=CC(Cl)=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 SQLBLEQZFKLJDH-UHFFFAOYSA-N 0.000 claims 1
- YILOROXHYKMRCS-UHFFFAOYSA-N 2-(6-chloro-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CC(Cl)=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 YILOROXHYKMRCS-UHFFFAOYSA-N 0.000 claims 1
- SLJARFDWGUAKRU-UHFFFAOYSA-N 2-(6-cyano-4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1COCCC1CC(N1C2=CC(=CC(=C2C=N1)S(=O)(=O)C1CC1)C#N)C(=O)NC1=CN=CC=N1 SLJARFDWGUAKRU-UHFFFAOYSA-N 0.000 claims 1
- XLQHBYCHEWPRHA-UHFFFAOYSA-N 2-(6-cyano-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=CC(=CC(=C2C=N1)S(=O)(=O)C1CC1)C#N)CC1CCOCC1 XLQHBYCHEWPRHA-UHFFFAOYSA-N 0.000 claims 1
- HHMLIFYECSOCDL-UHFFFAOYSA-N 2-(7-chloro-4-cyclopropylsulfonylindazol-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1C2=C(Cl)C=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 HHMLIFYECSOCDL-UHFFFAOYSA-N 0.000 claims 1
- XZUPKYAWZRPHSJ-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)sulfonylpyrazol-1-yl]-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C=1C=CC(Cl)=CC=1)CC1CCOCC1 XZUPKYAWZRPHSJ-UHFFFAOYSA-N 0.000 claims 1
- FYMSKXUOYCTAIF-UHFFFAOYSA-N 2-[4-cyclopropylsulfonyl-5-(difluoromethoxy)indazol-1-yl]-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound FC(F)OC1=CC=C2N(C(CC3CCOCC3)C(=O)NC=3SC(F)=CN=3)N=CC2=C1S(=O)(=O)C1CC1 FYMSKXUOYCTAIF-UHFFFAOYSA-N 0.000 claims 1
- ANRNYESBSXLHOJ-UHFFFAOYSA-N 2-[4-cyclopropylsulfonyl-6-(difluoromethoxy)indazol-1-yl]-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)C(CC2CCOCC2)N2C3=CC(OC(F)F)=CC(=C3C=N2)S(=O)(=O)C2CC2)=N1 ANRNYESBSXLHOJ-UHFFFAOYSA-N 0.000 claims 1
- MCLXSHBOZVYTIS-UHFFFAOYSA-N 2-[4-cyclopropylsulfonyl-6-(difluoromethoxy)indazol-1-yl]-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(OC(F)F)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 MCLXSHBOZVYTIS-UHFFFAOYSA-N 0.000 claims 1
- QAVCBIQSDBRVDD-UHFFFAOYSA-N 4-chloro-1-[1-[(5-chloro-1,3-thiazol-2-yl)amino]-3-(oxan-4-yl)-1-oxopropan-2-yl]-n-cyclopropylpyrazole-3-carboxamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1N=C(C(Cl)=C1)C(=O)NC1CC1)CC1CCOCC1 QAVCBIQSDBRVDD-UHFFFAOYSA-N 0.000 claims 1
- HAMZIZRSAJARRH-UHFFFAOYSA-N 4-cyclopropylsulfonyl-1-[1-[(5-fluoro-1,3-thiazol-2-yl)amino]-3-(oxan-4-yl)-1-oxopropan-2-yl]indazole-6-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 HAMZIZRSAJARRH-UHFFFAOYSA-N 0.000 claims 1
- KECNPRCEKFMIJE-HXUWFJFHSA-N 6-[[(2r)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanoyl]amino]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1NC(=O)[C@H](N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KECNPRCEKFMIJE-HXUWFJFHSA-N 0.000 claims 1
- KECNPRCEKFMIJE-UHFFFAOYSA-N 6-[[2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanoyl]amino]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1NC(=O)C(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KECNPRCEKFMIJE-UHFFFAOYSA-N 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- KFLBZKGZKGBQHB-UHFFFAOYSA-N n-(3-cyanopyridin-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound C1COCCC1CC(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=NC=CC=C1C#N KFLBZKGZKGBQHB-UHFFFAOYSA-N 0.000 claims 1
- BQSWORVDGGEXBI-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopentylsulfonylpyrazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C1CCCC1)CC1CCOCC1 BQSWORVDGGEXBI-UHFFFAOYSA-N 0.000 claims 1
- VTQVIQVSBYKGKQ-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonyl-6-fluoroindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound C12=CC(F)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 VTQVIQVSBYKGKQ-UHFFFAOYSA-N 0.000 claims 1
- AMNCFZVGAPBFJS-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 AMNCFZVGAPBFJS-UHFFFAOYSA-N 0.000 claims 1
- CFAZNSRHYWJWBC-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 CFAZNSRHYWJWBC-UHFFFAOYSA-N 0.000 claims 1
- ONNFBMFRNCTCOG-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(5-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1C2=CC=C(C=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 ONNFBMFRNCTCOG-UHFFFAOYSA-N 0.000 claims 1
- VAMVPDUYFAYBLF-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(6-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1C2=CC(=CC=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 VAMVPDUYFAYBLF-UHFFFAOYSA-N 0.000 claims 1
- FSPVEXPLKZQRDS-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-[4-(cyclopropylsulfonylamino)pyrazol-1-yl]-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1N=CC(NS(=O)(=O)C2CC2)=C1)CC1CCOCC1 FSPVEXPLKZQRDS-UHFFFAOYSA-N 0.000 claims 1
- WTYJLITUNJMKTC-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-2-(4-cyclopropylsulfonylpyrazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound N1=CC(Cl)=CC=C1NC(=O)C(N1N=CC(=C1)S(=O)(=O)C1CC1)CC1CCOCC1 WTYJLITUNJMKTC-UHFFFAOYSA-N 0.000 claims 1
- HZXIKWRMMBWBEB-UHFFFAOYSA-N n-(5-cyano-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound C1COCCC1CC(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=NC=C(C#N)S1 HZXIKWRMMBWBEB-UHFFFAOYSA-N 0.000 claims 1
- BQNMFZPAFDQFQC-UHFFFAOYSA-N n-(5-cyanopyridin-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound C1COCCC1CC(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=CC=C(C#N)C=N1 BQNMFZPAFDQFQC-UHFFFAOYSA-N 0.000 claims 1
- DZNMUYKELSJHII-UHFFFAOYSA-N n-(5-cyanopyrimidin-2-yl)-2-(4-cyclopropylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound C1COCCC1CC(N1C2=CC=CC(=C2C=N1)S(=O)(=O)C1CC1)C(=O)NC1=NC=C(C#N)C=N1 DZNMUYKELSJHII-UHFFFAOYSA-N 0.000 claims 1
- JLWNGYJNGVOKDE-UHFFFAOYSA-N n-(5-fluoro-1,3-thiazol-2-yl)-2-(4-methylsulfonylindazol-1-yl)-3-(oxan-4-yl)propanamide Chemical compound N1=CC=2C(S(=O)(=O)C)=CC=CC=2N1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 JLWNGYJNGVOKDE-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LYMBHJTVTFRHIJ-MRXNPFEDSA-N (2r)-2-(3-cyclopropylsulfonylpyrazol-1-yl)-n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C([C@H](C(=O)NC1=NC2=CC=C(N=C2S1)OC)N1N=C(C=C1)S(=O)(=O)C1CC1)C1CCOCC1 LYMBHJTVTFRHIJ-MRXNPFEDSA-N 0.000 abstract 1
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 49
- 125000001424 substituent group Chemical group 0.000 description 43
- 125000002993 cycloalkylene group Chemical group 0.000 description 30
- 238000000034 method Methods 0.000 description 30
- 229910052799 carbon Inorganic materials 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 239000007795 chemical reaction product Substances 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 238000000926 separation method Methods 0.000 description 16
- 125000002947 alkylene group Chemical group 0.000 description 15
- 125000001118 alkylidene group Chemical group 0.000 description 15
- 125000002619 bicyclic group Chemical group 0.000 description 15
- 125000004450 alkenylene group Chemical group 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 11
- 125000004419 alkynylene group Chemical group 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000001301 oxygen Chemical group 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000011593 sulfur Chemical group 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 235000001727 glucose Nutrition 0.000 description 10
- 229960001031 glucose Drugs 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 102000005548 Hexokinase Human genes 0.000 description 9
- 108700040460 Hexokinases Proteins 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 125000003367 polycyclic group Chemical group 0.000 description 9
- 108090000765 processed proteins & peptides Chemical group 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 125000006413 ring segment Chemical group 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 125000002723 alicyclic group Chemical group 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 229940124828 glucokinase activator Drugs 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Chemical group C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- UKAUYVFTDYCKQA-UHFFFAOYSA-N homoserine Chemical compound OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 208000035180 MODY Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000002820 allylidene group Chemical group [H]C(=[*])C([H])=C([H])[H] 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical group C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical group C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical group C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical group C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Chemical group 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical group C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical group C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 101150109586 Gk gene Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- NTISAKGPIGTIJJ-IUCAKERBSA-N Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C NTISAKGPIGTIJJ-IUCAKERBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical group C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical group C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Chemical group 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical group C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- INSWZAQOISIYDT-UHFFFAOYSA-N imidazo[1,2-a]pyrimidine Chemical compound C1=CC=NC2=NC=CN21 INSWZAQOISIYDT-UHFFFAOYSA-N 0.000 description 1
- PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical compound C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- VGPBPWRBXBKGRE-UHFFFAOYSA-N n-(oxomethylidene)hydroxylamine Chemical group ON=C=O VGPBPWRBXBKGRE-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- WMHRXFNTQPIYDT-UHFFFAOYSA-N pyrrolo[2,3-b]pyrazine Chemical compound C1=C[N]C2=NC=CC2=N1 WMHRXFNTQPIYDT-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- GDQBPBMIAFIRIU-UHFFFAOYSA-N thieno[2,3-c]pyridine Chemical compound C1=NC=C2SC=CC2=C1 GDQBPBMIAFIRIU-UHFFFAOYSA-N 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 125000005297 thienyloxy group Chemical group S1C(=CC=C1)O* 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5405208P | 2008-05-16 | 2008-05-16 | |
| US10837008P | 2008-10-24 | 2008-10-24 | |
| PCT/US2009/044190 WO2009140624A2 (en) | 2008-05-16 | 2009-05-15 | Glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ589084A true NZ589084A (en) | 2012-06-29 |
Family
ID=41076813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ589084A NZ589084A (en) | 2008-05-16 | 2009-05-15 | Glucokinase activators |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8563730B2 (OSRAM) |
| EP (1) | EP2294053B1 (OSRAM) |
| JP (1) | JP5513492B2 (OSRAM) |
| KR (1) | KR20110018366A (OSRAM) |
| CN (1) | CN102105451B (OSRAM) |
| AR (1) | AR071811A1 (OSRAM) |
| AU (1) | AU2009246167B2 (OSRAM) |
| BR (1) | BRPI0912802A2 (OSRAM) |
| CA (1) | CA2724116A1 (OSRAM) |
| CL (1) | CL2009001203A1 (OSRAM) |
| CO (1) | CO6321274A2 (OSRAM) |
| CR (1) | CR11827A (OSRAM) |
| DO (1) | DOP2010000351A (OSRAM) |
| EA (1) | EA018988B1 (OSRAM) |
| EC (1) | ECSP10010688A (OSRAM) |
| GE (1) | GEP20135783B (OSRAM) |
| IL (1) | IL209062A (OSRAM) |
| MA (1) | MA32391B1 (OSRAM) |
| MX (1) | MX2010012298A (OSRAM) |
| MY (1) | MY152749A (OSRAM) |
| NZ (1) | NZ589084A (OSRAM) |
| PE (2) | PE20091901A1 (OSRAM) |
| SG (1) | SG190625A1 (OSRAM) |
| TW (1) | TWI445707B (OSRAM) |
| UY (1) | UY31830A (OSRAM) |
| WO (1) | WO2009140624A2 (OSRAM) |
| ZA (1) | ZA201007975B (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2197280B1 (en) | 2007-08-27 | 2013-06-19 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| CA2713361A1 (en) * | 2008-02-05 | 2009-08-13 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| WO2009140624A2 (en) | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| PL2318390T3 (pl) | 2008-08-27 | 2013-09-30 | Takeda Pharmaceuticals Co | Związki pirolowe |
| EA201100311A1 (ru) * | 2008-09-11 | 2011-10-31 | Пфайзер Инк. | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы |
| WO2010034737A1 (en) * | 2008-09-24 | 2010-04-01 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| EP2451804B1 (en) | 2009-07-06 | 2014-04-30 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
| BR112012000149B8 (pt) | 2009-07-06 | 2021-01-12 | Basf Se | compostos de piridazina, método para controlar pragas invertebradas e método para proteger material de propagação de planta e/ou as plantas |
| US9125414B2 (en) | 2009-07-24 | 2015-09-08 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| ES2893699T3 (es) | 2010-03-31 | 2022-02-09 | Scripps Research Inst | Reprogramación de células |
| US9359313B2 (en) | 2010-05-26 | 2016-06-07 | Vtv Therapeutics Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| EP2627654A1 (en) | 2010-10-13 | 2013-08-21 | Takeda California, Inc. | Method of making azaindazole derivatives |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| ES2878001T3 (es) | 2012-05-17 | 2021-11-18 | Vtv Therapeutics Llc | Composiciones del activador de la glucocinasa para el tratamiento de la diabetes |
| EP2964198A2 (en) * | 2013-03-04 | 2016-01-13 | vTv Therapeutics LLC | Stable glucokinase activator compositions |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP3372586A1 (en) * | 2014-12-19 | 2018-09-12 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
| CN105092770B (zh) * | 2015-01-12 | 2017-03-29 | 上海中医药大学 | 一种筛选二肽基肽酶四抑制剂的方法 |
| WO2016202688A1 (en) | 2015-06-15 | 2016-12-22 | Bayer Cropscience Aktiengesellschaft | Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides |
| MX2017016363A (es) | 2015-06-15 | 2018-03-02 | Bayer Cropscience Ag | Fenoxifenilamidinas sustituidas con halogeno y el uso de estas como fungicidas. |
| EP3335559A1 (en) | 2016-12-14 | 2018-06-20 | Bayer CropScience Aktiengesellschaft | Active compound combinations |
| WO2018109002A1 (en) | 2016-12-14 | 2018-06-21 | Bayer Cropscience Aktiengesellschaft | Active compound combinations |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| WO2019228365A1 (zh) * | 2018-05-31 | 2019-12-05 | 华领医药技术(上海)有限公司 | 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合、组合物和复方制剂及其制备方法和用途 |
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| MX2022015525A (es) | 2020-06-08 | 2023-03-23 | Vtv Therapeutics Llc | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE910278A1 (en) | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| GB9315846D0 (en) | 1993-07-30 | 1993-09-15 | Isis Innovation | Tumour inhibitors |
| US5795726A (en) | 1996-11-12 | 1998-08-18 | Millennium Pharmaceuticals, Inc. | Methods for identifying compounds useful in treating type II diabetes |
| GB9806692D0 (en) | 1998-03-27 | 1998-05-27 | Pharmacia & Upjohn Spa | Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents |
| CN1151140C (zh) | 1999-03-29 | 2004-05-26 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
| US20030013633A1 (en) | 1999-06-07 | 2003-01-16 | Rima Kaddurah-Daouk | Use of molecules that modulate an energy related associated state |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| KR20100130651A (ko) | 1999-12-23 | 2010-12-13 | 노파르티스 아게 | 당 대사 장애를 치료하기 위한 혈당강하제의 용도 |
| EP1280801B1 (en) | 2000-05-03 | 2005-09-07 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| DK1283830T3 (da) | 2000-05-08 | 2008-08-25 | Hoffmann La Roche | Para-amin-substituerede phenylamidglucokinase-aktivatorer |
| ATE297907T1 (de) | 2000-07-20 | 2005-07-15 | Hoffmann La Roche | Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase- aktivatoren |
| US6433188B1 (en) | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| US7358267B2 (en) | 2001-06-29 | 2008-04-15 | Amgen Inc. | Bis-aryl thiazole derivatives |
| EP1453541A1 (en) | 2001-12-03 | 2004-09-08 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| BR0215212A (pt) | 2001-12-21 | 2004-12-07 | Novo Nordisk As | Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto |
| CA2488161A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| US20040053948A1 (en) | 2002-05-10 | 2004-03-18 | Cytokinetics, Inc. | Compounds, compositions and methods |
| EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
| GB0216097D0 (en) | 2002-07-11 | 2002-08-21 | Univ London | Treatment of proliferative disorders |
| AU2003275029A1 (en) | 2002-09-27 | 2004-04-19 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| RU2005113713A (ru) | 2002-10-03 | 2006-01-20 | Новартис АГ (CH) | Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2 |
| PL375149A1 (en) | 2002-10-03 | 2005-11-28 | F.Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
| EP1556088A2 (en) | 2002-10-29 | 2005-07-27 | Engene, Inc. | Compositions for cancer treatment |
| CA2509086C (en) | 2003-01-06 | 2012-08-21 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
| JP4621198B2 (ja) | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ(シクロ)置換アミドグルコキナーゼ活性化化合物 |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7179613B2 (en) | 2003-05-05 | 2007-02-20 | Vanderbilt University | Methods of screening for a candidate modulator of glucokinase |
| GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| WO2005052132A2 (en) | 2003-11-24 | 2005-06-09 | Exelixis, Inc | Mbms as modifiers of branching morphogenesis and methods of use |
| GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| ATE524479T1 (de) | 2004-04-02 | 2011-09-15 | Novartis Ag | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren |
| NZ550567A (en) | 2004-04-21 | 2010-07-30 | Prosidion Ltd | Tri(cyclo) substituted amide compounds |
| ES2590259T3 (es) | 2004-06-17 | 2016-11-21 | Wisconsin Alumni Research Foundation | Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos |
| US20080026987A1 (en) | 2004-06-17 | 2008-01-31 | Novo Nordisk A/S | Use of Liver-Selective Glucokinase Activators |
| AU2005271016A1 (en) | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
| US20070292478A1 (en) | 2004-08-30 | 2007-12-20 | Popowski Youri | Medical Implant Provided with Inhibitors of Atp Synthesis |
| EP1891971A4 (en) | 2005-01-31 | 2010-02-03 | Ajinomoto Kk | MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA |
| AU2006262490A1 (en) | 2005-06-22 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Targets for inhibiting HCV replication |
| US7565029B2 (en) * | 2005-07-08 | 2009-07-21 | Seiko Epson Corporation | Method for determining camera position from two-dimensional images that form a panorama |
| TWI359149B (en) | 2005-07-11 | 2012-03-01 | Mitsubishi Tanabe Pharma Corp | An oxime derivative and preparations thereof |
| BRPI0615236A2 (pt) | 2005-08-31 | 2011-05-10 | Astellas Pharma Inc | derivado de tiazol |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
| CA2628486A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd. | Tricyclo substituted amides |
| EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2007075847A2 (en) | 2005-12-20 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Glucokinase activators |
| EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2007115968A2 (en) | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a glucokinase activator |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| US7842713B2 (en) | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| ATE522518T1 (de) * | 2006-05-31 | 2011-09-15 | Takeda San Diego Inc | Indazol- und isoindolderivate als glucokinaseaktivierende stoffe |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| WO2008153814A2 (en) | 2007-05-29 | 2008-12-18 | President And Fellows Of Harvard College | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
| WO2009022179A2 (en) | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| WO2009140624A2 (en) | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| JP2013522294A (ja) | 2010-03-18 | 2013-06-13 | タケダ カリフォルニア インコーポレイテッド | 2−アミノ−5−フルオロチアゾールの製造プロセス |
| EP2627654A1 (en) | 2010-10-13 | 2013-08-21 | Takeda California, Inc. | Method of making azaindazole derivatives |
-
2009
- 2009-05-15 WO PCT/US2009/044190 patent/WO2009140624A2/en not_active Ceased
- 2009-05-15 SG SG2013034012A patent/SG190625A1/en unknown
- 2009-05-15 AU AU2009246167A patent/AU2009246167B2/en not_active Ceased
- 2009-05-15 EP EP09747705.3A patent/EP2294053B1/en not_active Not-in-force
- 2009-05-15 US US12/467,041 patent/US8563730B2/en not_active Expired - Fee Related
- 2009-05-15 NZ NZ589084A patent/NZ589084A/en not_active IP Right Cessation
- 2009-05-15 TW TW98116300A patent/TWI445707B/zh not_active IP Right Cessation
- 2009-05-15 KR KR20107028256A patent/KR20110018366A/ko not_active Ceased
- 2009-05-15 MX MX2010012298A patent/MX2010012298A/es active IP Right Grant
- 2009-05-15 BR BRPI0912802A patent/BRPI0912802A2/pt not_active IP Right Cessation
- 2009-05-15 PE PE2009000690A patent/PE20091901A1/es not_active Application Discontinuation
- 2009-05-15 CA CA 2724116 patent/CA2724116A1/en not_active Abandoned
- 2009-05-15 GE GEAP2009012029 patent/GEP20135783B/en unknown
- 2009-05-15 EA EA201071320A patent/EA018988B1/ru not_active IP Right Cessation
- 2009-05-15 MY MYPI20105245 patent/MY152749A/en unknown
- 2009-05-15 PE PE2014000756A patent/PE20141375A1/es not_active Application Discontinuation
- 2009-05-15 CL CL2009001203A patent/CL2009001203A1/es unknown
- 2009-05-15 UY UY31830A patent/UY31830A/es not_active Application Discontinuation
- 2009-05-15 JP JP2011509762A patent/JP5513492B2/ja not_active Expired - Fee Related
- 2009-05-15 AR ARP090101763 patent/AR071811A1/es unknown
- 2009-05-15 CN CN2009801273588A patent/CN102105451B/zh not_active Expired - Fee Related
-
2010
- 2010-11-01 IL IL209062A patent/IL209062A/en not_active IP Right Cessation
- 2010-11-08 ZA ZA2010/07975A patent/ZA201007975B/en unknown
- 2010-11-15 DO DO2010000351A patent/DOP2010000351A/es unknown
- 2010-12-07 CO CO10154094A patent/CO6321274A2/es not_active Application Discontinuation
- 2010-12-07 CR CR11827A patent/CR11827A/es unknown
- 2010-12-10 MA MA33420A patent/MA32391B1/fr unknown
- 2010-12-16 EC ECSP10010688 patent/ECSP10010688A/es unknown
-
2012
- 2012-04-10 US US13/443,774 patent/US20120225887A1/en not_active Abandoned
-
2013
- 2013-10-02 US US14/044,687 patent/US9139598B2/en not_active Expired - Fee Related
-
2015
- 2015-09-21 US US14/860,573 patent/US20160009735A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009246167B2 (en) | Glucokinase activators | |
| US8034822B2 (en) | Glucokinase activators | |
| US8173645B2 (en) | Glucokinase activators | |
| US8530499B2 (en) | Glucokinase activators | |
| US8008332B2 (en) | Substituted indazoles as glucokinase activators | |
| US20070244169A1 (en) | Glucokinase activators | |
| US20100105665A1 (en) | Renin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: CORRECTION TO INVENTORS (72) |
|
| ASS | Change of ownership |
Owner name: TAKEDA CALIFORNIA, US Free format text: OLD OWNER(S): TAKEDA SAN DIEGO, INC. |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 MAY 2016 BY ANDY BREEDEN Effective date: 20130529 |
|
| LAPS | Patent lapsed |